Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical study is to assess the safety of PLX-PAD to treat pulmonary
arterial hypertension (PAH). PLX-PAD is a cell-based product made of allogeneic
Mesenchymal-like Adherent Stromal Cells (ASCs), derived from human full-term placentas
following an elective caesarean section. This year-long study will evaluate the safety of
three different dose levels of PLX-PAD, each given as a single intravenous infusion. This
study will also evaluate effects that PLX-PAD may have on PAH, such as changes in the ability
to exercise and on other tests used to measure the disease severity.